STOCK TITAN

Cidara Therapeutics, Inc. - $CDTX STOCK NEWS

Welcome to our dedicated page for Cidara Therapeutics news (Ticker: $CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics stock.

Cidara Therapeutics, Inc. (CDTX), headquartered in San Diego, California, is a pioneering biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. The company's mission is to address diseases inadequately treated by current standard of care therapies. Utilizing its proprietary Cloudbreak® platform, Cidara develops drug-Fc conjugates (DFCs) aimed at saving lives and improving patient outcomes for serious diseases such as cancer, viral infections, and autoimmune diseases.

The company's core portfolio includes:

  • Rezafungin (REZZAYO™): An FDA and EC-approved treatment for invasive candidiasis, licensed to multiple partners for commercialization in the U.S. and internationally.
  • CD101 IV: A potential once-weekly intravenous therapy for systemic fungal infections.
  • CD101 Topical: The first topical application of the echinocandin class of anti-fungals for vulvovaginal candidiasis (VVC).
  • CD388: A long-acting antiviral investigational drug for the prevention of all strains of influenza A and B, currently in Phase 2b development.

Recent achievements include significant data presentations at prestigious conferences and strategic realignments to focus on the most promising components of their pipeline. Cidara’s financial stability is reinforced by a $240 million private placement led by RA Capital Management, with participation from top-tier investors like Bain Capital Life Sciences and Biotech Value Fund (BVF).

Noteworthy partnerships include collaborations with Johnson & Johnson for CD388 and Mundipharma for the divestiture of rezafungin, which has led to substantial cost savings and allows Cidara to focus on its Cloudbreak platform. The company is also preparing for a Phase 2b clinical trial of CD388, aiming to deliver universal, season-long protection against influenza.
For more information, visit www.cidara.com.

Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) announced it will present preclinical data on CD388 at the ASM Microbe 2024 conference, from June 13-17, 2024, in Atlanta, Georgia. CD388 is a novel Drug-Fc Conjugate (DFC) being developed for influenza prevention, using Cidara's proprietary Cloudbreak® platform. The presentation, led by Dr. Voon Ong, will focus on comparing different allometric scaling approaches to project human pharmacokinetics (PK) of CD388. The session, titled 'AAR07 Saturday Antimicrobial Pharmacokinetics and Pharmacodynamics,' will take place on June 15, 2024, from 10:00 AM to 5:00 PM ET at the Exhibit Hall, poster board number AAR-SATURDAY-494.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
conferences clinical trial
-
Rhea-AI Summary

Cidara Therapeutics (CDTX) announced its Q1 2024 financial results and corporate updates. The company reacquired the global rights to CD388, a universal influenza preventative, from Janssen, and sold its rezafungin program to Mundipharma, aiming to save around $128 million in costs. Cidara raised $240 million through a private placement, led by RA Capital Management. Q1 2024 revenue was $8.5 million, down from $26.1 million in Q1 2023. The company reported a net loss of $10.3 million, compared to a net income of $3.0 million in Q1 2023. R&D expenses decreased to $11.6 million, while SG&A expenses increased to $6.0 million. Cidara conducted a 1-for-20 reverse stock split in April 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
-
Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) announced it has regained compliance with Nasdaq's continued listing rules as of May 14, 2024. The company received confirmation from the Nasdaq Listing Qualifications Department. However, the Nasdaq Hearing Panel has imposed a discretionary monitor until May 14, 2025. During this period, any failure to maintain compliance will result in a delist determination letter and a subsequent hearing to address the issue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
none
Rhea-AI Summary
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential for seasonal influenza prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
-
Rhea-AI Summary
Cidara Therapeutics reacquires global development and commercial rights to CD388 and announces a private placement financing of $240 million. The financing, led by RA Capital Management, aims to fund the Phase 2b clinical trial of CD388, an antiviral drug for influenza A and B. The company plans to develop CD388 as a universal preventative against seasonal and pandemic influenza. Johnson & Johnson has transferred exclusive rights to CD388 back to Cidara in exchange for an $85 million upfront payment and potential milestone payments. The private placement will support the development of CD388 through Phase 2b and beyond, with a focus on providing long-acting, universal protection against all forms of influenza. The company is set to host a business strategy update conference call and webcast to discuss the recent developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
none
-
Rhea-AI Summary
Cidara Therapeutics announced the divestiture of rezafungin to Mundipharma to focus on advancing the Cloudbreak DFC pipeline. The transaction will provide an estimated $128 million in cost savings over the patent life of rezafungin, enabling Cidara to focus on advancing its Cloudbreak development programs, including an IND filing for its lead oncology candidate, CBO421. Mundipharma will now hold commercial rights to rezafungin outside the U.S. and Japan, with ongoing obligations related to the ReSPECT Phase 3 clinical trial and regulatory requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
Rhea-AI Summary
Cidara Therapeutics, Inc. reported financial results for Q4 and full year 2023, highlighted key achievements in their Cloudbreak® platform and REZZAYO® program, including approvals in the EU and UK. The company presented new data at various medical meetings and completed enrollment in a Phase 3 trial in China. Revenue increased, cash reserves grew, and net losses decreased compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary
Cidara Therapeutics, a biotechnology company, received a delinquency notice from Nasdaq for failing to file its Annual Report on Form 10-K. The company plans to submit its compliance plan and has implemented a 1-for-20 reverse stock split to maintain its listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary
Cidara Therapeutics, a biotechnology company, announced a 1-for-20 reverse stock split of its common stock. The reverse split will be effective on April 23, 2024, with trading on a split-adjusted basis starting on April 24, 2024. This decision was made following a stockholder vote and board approval to enhance the stock's value and reduce the number of outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.54%
Tags
Rhea-AI Summary
Cidara Therapeutics, Inc. (CDTX) announced promising preclinical data on its drug-Fc conjugate (DFC) immunotherapies at the AACR Annual Meeting. The multispecific CD73/PD-1 DFC showed improved tumor reduction over PD-1 monotherapy, CCR5-targeting DFC demonstrated efficacy in colorectal cancer, and CBO421 outperformed oleclumab in triple-negative breast cancer cell lines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
none

FAQ

What is Cidara Therapeutics' primary focus?

Cidara Therapeutics focuses on discovering, developing, and commercializing novel anti-infectives and immunotherapies for diseases inadequately treated by current therapies.

What is the Cloudbreak® platform?

The Cloudbreak® platform is Cidara's proprietary technology used to develop drug-Fc conjugates (DFCs) that target serious diseases by combining small molecules and peptides with human antibody fragments.

What are some of Cidara's key products?

Key products include REZZAYO™ (rezafungin) for invasive candidiasis, CD101 IV for systemic fungal infections, CD101 Topical for vulvovaginal candidiasis, and CD388 for the prevention of influenza A and B.

Has Cidara received any approvals for its products?

Yes, Cidara has received FDA and EC approval for REZZAYO™ (rezafungin) for the treatment of invasive candidiasis.

What recent strategic decisions has Cidara made?

Cidara recently divested rezafungin to Mundipharma, resulting in significant cost savings, and reacquired the global rights to CD388 from Johnson & Johnson to focus on their Cloudbreak platform.

How is Cidara funded?

Cidara is funded through investments, including a $240 million private placement led by RA Capital Management, and milestone payments from collaborations with partners like Mundipharma and Johnson & Johnson.

What upcoming clinical trials does Cidara have?

Cidara is planning to initiate a Phase 2b clinical trial to evaluate the efficacy and safety of CD388 as a universal preventative for influenza.

Where is Cidara Therapeutics headquartered?

Cidara Therapeutics is headquartered in San Diego, California.

Who are Cidara's major partners?

Major partners include Johnson & Johnson for CD388 and Mundipharma for rezafungin.

How can I get more information about Cidara?

For more information, you can visit Cidara's official website at www.cidara.com.

Cidara Therapeutics, Inc.

Nasdaq:CDTX

CDTX Rankings

CDTX Stock Data

61.31M
76.81M
7.53%
30.63%
0.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO